IMpower133試験、初回の中間解析で複合主要評価項目を達成

進展型小細胞肺がんの初回治療においてアテゾリズマブ+化学療法がPFSおよびOSを改善

IMpower133 Study Met Co-primary Endpoints at First Interim Analysis


Atezolizumab plus chemotherapy combination show improvement in progression-free and overall survival in the initial treatment of extensive-stage small cell lung cancer

 

 

 

コメント

Leave a comment

Your email address will not be published.


*